Colorectal Surgery
MD, PhD, FRCS, Professor, Chief Physician, Doctoral Supervisor and Director of the Colorectal Cancer Center, West China Hospital, Sichuan University, China
Dr. Ziqiang Wang is a distinguished professor and Ph.D. supervisor at West China Hospital, Sichuan University, specializing in colorectal surgery and minimally invasive surgery. As the Director of the Colorectal Cancer Center, he performs over 600 colorectal surgeries annually. Dr. Wang proposed small vessels on mesorectal and parietal abdominal and pelvic fascia as novel landmarks for inter-fascial dissection in colorectal surgery. He introduced several innovative surgical procedures, including a unidirectionally progressive, pancreas-oriented procedure for laparoscopic D3 right hemicolectomy, a bladder peritoneum flap closure for the pelvic cavity after laparoscopic TME, and retro-muscular mesh placement in a Sugarbaker configuration through a laparoscopic-assisted extra-peritoneal route for end colostomy.
He pioneered the combined use of chemo-radiotherapy and selective lateral lymph node dissection for mid-low rectal cancer in China and drafted the “Expert Consensus on the Diagnosis and Treatment of Lateral Lymph Node Metastasis in Rectal Cancer (2019 and 2024 editions).” Dr. Wang is the convener of the multidisciplinary team (MDT) for colorectal cancer comprehensive treatment discussions at his hospital.
Dr. Wang has initiated and completed three multi-center clinical trials in China to address the necessity and effectiveness of selective use of neoadjuvant therapy in rectal cancer according to risk factors, including total neoadjuvant chemoradiotherapy for high-risk patients, chemotherapy for patients with intermediate risks, and the efficacy and timing of early response assessment for neoadjuvant chemotherapy. He has secured two National Natural Science Foundation projects, one Ministry of Science and Technology’s 135 Key Project, and five provincial and ministerial-level research projects.
In the laboratory, Dr. Wang’s research focuses on the mechanisms of exosomes in colorectal cancer liver and peritoneal metastasis, molecular prognosis of colorectal cancer, and artificial intelligence in colorectal cancer diagnosis. He has published over 200 SCI articles.
Selected publications from PubMed
Colorectal neuroendocrine neoplasm organoids reveal the potential therapeutic value of targeting BRAF mutations.
Chen Y, Fan B, Zhang Y, Wang Z
J Endocr Soc. 2026 Oct;10(10):bvag196 doi: 10.1210/jendso/bvag196.
LC-MS/MS-based clinical value exploration of the methionine cycle in luminal breast cancer.
Wu W, Tu Y, Yao H, Mao Y, Mao C, Xu F, Wang Z
Oncol Lett. 2026 Oct;32(4):440 doi: 10.3892/ol.2026.15795.
Developing Personalized Postoperative Follow-Up Strategies for Patients With Locally Advanced Gastric Cancer Receiving Neoadjuvant Therapy Based on Dynamic Programming: A Multicenter Retrospective Cohort Study in China.
Li T, Yang Z, Liu C, Lian L, Lin J, Zhang P, Xiao H, Wang X, Tang Z, Li W, Tao K, Sheng W, Cao Y, Wang L, Sun J, Zhang Z, Shi Z, Yin J, Wang Z, Cao S, Yuan S, Liu X, Shang L, Zhao Y, Tao K
Int J Cancer. 2026 Sep 1 doi: 10.1002/ijc.70731.
First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.
Liu Y, Zhang Y, Lin R, Chen X, Wang J, Yang M, Qu X, Li Y, Li J, Zhang W, Mao Y, Wang Z, Liu Z, Lei J, Xu Y, Jiang Y, Pan Z, Zhu L, Liu C, Song M, Yuan Y, Ding K, ANCHOR Study Group
Signal Transduct Target Ther. 2026 Sep 1;11(1) doi: 10.1038/s41392-026-02938-4.
MMP-2 rs243865 Polymorphism as a Risk Modifier of Hepatocellular Carcinoma in Taiwanese Males, Smokers and Alcohol Consumers.
Yueh TC, Wu MH, Yang MD, Lu MC, Shao YC, Ke TW, Wang ZH, Chen CA, Tsai CW, Bau DT, Chang WS
Anticancer Res. 2026 Sep;46(9):4867-4880 doi: 10.21873/anticanres.18339.
Help your network discover Dr. Ziqiang Wang's clinical expertise.
